{"id":"W2755704235","doi":"10.1136/annrheumdis-2017-eular.1580","title":"SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dermatrials Research","funders":"","keywords":"Ixekizumab; Psoriatic arthritis; Medicine; Dermatology Life Quality Index; Quality of life (healthcare); Presenteeism; Placebo; Psoriasis; Internal medicine; Visual analogue scale; Physical therapy; Adalimumab; Tumor necrosis factor alpha; Arthritis; Secukinumab; Absenteeism; Dermatology; Pathology; Alternative medicine; Psychology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007367869,0.0002166746,0.000692806,0.0001480766,0.0001536344,0.0004890363,0.0001664314,0.0002727757,0.002098666],"category_scores_gemma":[0.001466021,0.0001149588,0.000701158,0.0002110317,0.0001210374,0.0003004201,0.0001817012,0.0006786971,0.0002241854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001989666,"about_ca_system_score_gemma":0.000219644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005321453,"about_ca_topic_score_gemma":0.001166351,"domain_scores_codex":[0.9996448,0.000122753,0.00005361295,0.00004219687,0.0000618615,0.00007477737],"domain_scores_gemma":[0.9990996,0.0002372251,0.0004064594,0.00004347407,0.00006660212,0.0001466364],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.07880135,0.00393778,0.5388037,0.0009616757,0.005210975,0.0004973274,0.0002027367,0.001197012,0.007115858,0.0001940918,0.006337648,0.3567399],"study_design_scores_gemma":[0.00577759,0.01667761,0.9676968,0.0001269457,0.00216097,0.001220903,0.0002074954,0.001534087,0.001100065,0.0002636983,0.003204168,0.00002945218],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917259,0.005511924,0.00009897038,0.0004287331,0.0001207246,0.00001469819,0.0002345075,0.00001920391,0.00184531],"genre_scores_gemma":[0.9983189,0.000750459,0.00007714614,0.0001826918,0.000101952,0.000007340323,0.000211224,0.000001554579,0.0003486419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002098666,"threshold_uncertainty_score":0.007020772,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01713395734756117,"score_gpt":0.2559271969964671,"score_spread":0.2387932396489059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}